FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056335887> ?p ?o ?g. }

• W2056335887 endingPage "405" @default.
• W2056335887 startingPage "399" @default.
• W2056335887 abstract "Abstract: Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double‐blinded, randomized, multi‐center study we assessed histological changes in 110 hepatitis B e‐antigen (HBeAg)‐positive CHB patients treated for 52 weeks with Pegylated interferon α‐2b (PEG‐IFN) in combination with either lamivudine or placebo. Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system. Results: Necroinflammatory score improved (defined as a decrease of at least two points) in 25 patients (48%) of the PEG‐IFN/lamivudine combination therapy group and in 31 patients (53%) of the PEG‐IFN monotherapy group. The fibrosis score improved (decrease of at least 1 point) in 17 patients (33%) of the combination therapy group vs. 13 patients (22%) of the PEG‐IFN monotherapy group ( P =0.23). Responders ( n =42), defined as serum HBeAg negative at the end of therapy, showed a larger decline in necroinflammatory score than non‐responders (mean decline 2.3 and 1.2 points, respectively, P =0.02). Among patients receiving PEG‐IFN monotherapy necroinflammation improved more frequently in responders (78% of responders vs. 43% of non‐responders, P =0.01) and in patients who showed normalization of ALT (76% of patients with normal ALT vs. 40% of patients with abnormal ALT, P =0.01). Fibrosis score in the PEG‐IFN monotherapy group improved more often in responders (39%) than in non‐responders (15%, P =0.04). In the PEG‐IFN/lamivudine combination therapy group, we found no significant association between virological and biochemical endpoints and histological improvement. Conclusions: Treatment with PEG‐IFN therapy improves liver necroinflammation in HBeAg‐positive CHB patients, particularly in responders to therapy. PEG‐IFN also improves fibrosis in responders. Addition of lamivudine to PEG‐IFN did not further improve the histological outcome." @default.
• W2056335887 created "2016-06-24" @default.
• W2056335887 creator A5003885788 @default.
• W2056335887 creator A5005200745 @default.
• W2056335887 creator A5008202438 @default.
• W2056335887 creator A5032528530 @default.
• W2056335887 creator A5034065954 @default.
• W2056335887 creator A5036482660 @default.
• W2056335887 creator A5043626370 @default.
• W2056335887 creator A5060952649 @default.
• W2056335887 creator A5083057475 @default.
• W2056335887 creator A5083821618 @default.
• W2056335887 date "2006-04-10" @default.
• W2056335887 modified "2023-10-14" @default.
• W2056335887 title "Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine" @default.
• W2056335887 cites W1950099322 @default.
• W2056335887 cites W1964039671 @default.
• W2056335887 cites W2008517556 @default.
• W2056335887 cites W2014837723 @default.
• W2056335887 cites W2058793169 @default.
• W2056335887 cites W2076506726 @default.
• W2056335887 cites W2080842217 @default.
• W2056335887 cites W2093604720 @default.
• W2056335887 cites W2101032357 @default.
• W2056335887 cites W2136425954 @default.
• W2056335887 cites W2319441763 @default.
• W2056335887 cites W2338794667 @default.
• W2056335887 cites W2341203768 @default.
• W2056335887 cites W3152231134 @default.
• W2056335887 cites W4362208329 @default.
• W2056335887 doi "https://doi.org/10.1111/j.1478-3231.2006.01257.x" @default.
• W2056335887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16629642" @default.
• W2056335887 hasPublicationYear "2006" @default.
• W2056335887 type Work @default.
• W2056335887 sameAs 2056335887 @default.
• W2056335887 citedByCount "36" @default.
• W2056335887 countsByYear W20563358872012 @default.
• W2056335887 countsByYear W20563358872013 @default.
• W2056335887 countsByYear W20563358872014 @default.
• W2056335887 countsByYear W20563358872015 @default.
• W2056335887 countsByYear W20563358872017 @default.
• W2056335887 countsByYear W20563358872018 @default.
• W2056335887 countsByYear W20563358872019 @default.
• W2056335887 countsByYear W20563358872020 @default.
• W2056335887 countsByYear W20563358872021 @default.
• W2056335887 crossrefType "journal-article" @default.
• W2056335887 hasAuthorship W2056335887A5003885788 @default.
• W2056335887 hasAuthorship W2056335887A5005200745 @default.
• W2056335887 hasAuthorship W2056335887A5008202438 @default.
• W2056335887 hasAuthorship W2056335887A5032528530 @default.
• W2056335887 hasAuthorship W2056335887A5034065954 @default.
• W2056335887 hasAuthorship W2056335887A5036482660 @default.
• W2056335887 hasAuthorship W2056335887A5043626370 @default.
• W2056335887 hasAuthorship W2056335887A5060952649 @default.
• W2056335887 hasAuthorship W2056335887A5083057475 @default.
• W2056335887 hasAuthorship W2056335887A5083821618 @default.
• W2056335887 hasConcept C126322002 @default.
• W2056335887 hasConcept C142724271 @default.
• W2056335887 hasConcept C203014093 @default.
• W2056335887 hasConcept C204787440 @default.
• W2056335887 hasConcept C2522874641 @default.
• W2056335887 hasConcept C27081682 @default.
• W2056335887 hasConcept C2775940106 @default.
• W2056335887 hasConcept C2776461080 @default.
• W2056335887 hasConcept C2776999253 @default.
• W2056335887 hasConcept C2777382497 @default.
• W2056335887 hasConcept C2777410769 @default.
• W2056335887 hasConcept C2777869810 @default.
• W2056335887 hasConcept C2780040827 @default.
• W2056335887 hasConcept C2780593183 @default.
• W2056335887 hasConcept C3020491458 @default.
• W2056335887 hasConcept C71924100 @default.
• W2056335887 hasConcept C90924648 @default.
• W2056335887 hasConceptScore W2056335887C126322002 @default.
• W2056335887 hasConceptScore W2056335887C142724271 @default.
• W2056335887 hasConceptScore W2056335887C203014093 @default.
• W2056335887 hasConceptScore W2056335887C204787440 @default.
• W2056335887 hasConceptScore W2056335887C2522874641 @default.
• W2056335887 hasConceptScore W2056335887C27081682 @default.
• W2056335887 hasConceptScore W2056335887C2775940106 @default.
• W2056335887 hasConceptScore W2056335887C2776461080 @default.
• W2056335887 hasConceptScore W2056335887C2776999253 @default.
• W2056335887 hasConceptScore W2056335887C2777382497 @default.
• W2056335887 hasConceptScore W2056335887C2777410769 @default.
• W2056335887 hasConceptScore W2056335887C2777869810 @default.
• W2056335887 hasConceptScore W2056335887C2780040827 @default.
• W2056335887 hasConceptScore W2056335887C2780593183 @default.
• W2056335887 hasConceptScore W2056335887C3020491458 @default.
• W2056335887 hasConceptScore W2056335887C71924100 @default.
• W2056335887 hasConceptScore W2056335887C90924648 @default.
• W2056335887 hasIssue "4" @default.
• W2056335887 hasLocation W20563358871 @default.
• W2056335887 hasLocation W20563358872 @default.
• W2056335887 hasOpenAccess W2056335887 @default.
• W2056335887 hasPrimaryLocation W20563358871 @default.
• W2056335887 hasRelatedWork W1995937523 @default.
• W2056335887 hasRelatedWork W2000911773 @default.
• W2056335887 hasRelatedWork W2051078532 @default.

• next